Drug intelligence / Profile preview

SBP-302

Development stage: Preclinical
Lead developer: SML Biopharm
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intramuscular, Intravenous, Subcutaneous, Intradermal

Overview

SBP-302 is an mRNA-based therapeutic candidate developed by SML Biopharm for the treatment of sarcopenia. Part of the company's 'In-vivo Protein Expression Therapeutics' pipeline, SBP-302 utilizes a proprietary lipid nanoparticle (LNP) delivery system to facilitate the intracellular expression of a novel protein target. By leveraging mRNA technology to induce protein production directly within the patient's tissues, the therapy aims to mitigate the muscle mass loss and functional impairment characteristic of sarcopenia. The program is currently in the candidate optimization phase, focusing on refining the mRNA sequence and LNP formulation for optimal protein expression and therapeutic efficacy.

Beyond the preview

Go deeper on SBP-302.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBP-302.

Explore the full profile